Want to see KROS full AI Analyst Report?
Total Valuation
Keros Therapeutics has a market cap or net worth of $218.69M. The enterprise value is -$30.02.
Market Cap$218.69M
Enterprise Value-$30.02
Share Statistics
Keros Therapeutics has 19,827,188 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,827,188
Owned by Insiders5.19%
Owned by Institutions21.63%
Financial Efficiency
Keros Therapeutics’s return on equity (ROE) is 0.29 and return on invested capital (ROIC) is 20.90%.
Return on Equity (ROE)0.29
Return on Assets (ROA)0.26
Return on Invested Capital (ROIC)20.90%
Return on Capital Employed (ROCE)0.22
Revenue Per Employee2.65M
Profits Per Employee945.80K
Employee Count92
Asset Turnover0.72
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Keros Therapeutics is ―. Keros Therapeutics’s PEG ratio is -0.06.
PE Ratio―
PS Ratio3.11
PB Ratio2.50
Price to Fair Value2.50
Price to FCF7.15
Price to Operating Cash Flow-4.45
PEG Ratio-0.06
Income Statement
In the last 12 months, Keros Therapeutics had revenue of 244.06M and earned 87.01M in profits. Earnings per share was 2.34.
Revenue244.06M
Gross Profit242.55M
Operating Income70.62M
Pretax Income91.90M
Net Income87.01M
EBITDA93.41M
Earnings Per Share (EPS)2.34
Cash Flow
In the last 12 months, operating cash flow was -47.99M and capital expenditures -494.00K, giving a free cash flow of -48.49M billion.
Operating Cash Flow-47.99M
Free Cash Flow-48.49M
Free Cash Flow per Share-2.45
Dividends & Yields
Keros Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.09
52-Week Price Change-26.96%
50-Day Moving Average10.68
200-Day Moving Average13.90
Relative Strength Index (RSI)51.56
Average Volume (3m)282.35K
Important Dates
Keros Therapeutics upcoming earnings date is Nov 11, 2026, Before Open (Confirmed).
Last Earnings DateAug 3, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Keros Therapeutics as a current ratio of 15.45, with Debt / Equity ratio of 5.99%
Current Ratio15.45
Quick Ratio15.45
Debt to Market Cap0.00
Net Debt to EBITDA-2.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Keros Therapeutics has paid 4.88M in taxes.
Income Tax4.88M
Effective Tax Rate0.05
Enterprise Valuation
Keros Therapeutics EV to EBITDA ratio is 5.22, with an EV/FCF ratio of 4.60.
EV to Sales2.00
EV to EBITDA5.22
EV to Free Cash Flow4.60
EV to Operating Cash Flow4.53
Balance Sheet
Keros Therapeutics has $257.61M in cash and marketable securities with $15.72M in debt, giving a net cash position of $241.88M billion.
Cash & Marketable Securities$257.61M
Total Debt$15.72M
Net Cash$241.88M
Net Cash Per Share$12.20
Tangible Book Value Per Share$8.14
Margins
Gross margin is 94.68%, with operating margin of 28.94%, and net profit margin of 35.65%.
Gross Margin94.68%
Operating Margin28.94%
Pretax Margin37.65%
Net Profit Margin35.65%
EBITDA Margin38.27%
EBIT Margin37.65%
Analyst Forecast
The average price target for Keros Therapeutics is $18.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$18.80
Price Target Upside86.88% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast-93.55%
EPS Growth Forecast-1143.58%